ClinicalTrials.gg
TerminatedNCT02393209Updated Feb 7, 2018Results posted

Docetaxel With or Without TAK-117 (MLN1117) in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 1/2 interventional study of Docetaxel and TAK-117 in Non-small Cell Lung Cancer, sponsored by Millennium Pharmaceuticals, Inc.. Terminated at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-07.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
Lack of efficacy in combination.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda — 1 open to participants now, 4 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · Takeda.

Enrollment
16th of 17
14 · median 101
Started
2015
the only one that year
Phase 1/2
6 of 31
none open now
Registered
8th of 31
by date

Among the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, this one is the 16th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2015, is one of 6 in phase 1/2, and was the 8th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

1 of the 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Carcinoma, Non-Small-Cell Lung by Takeda, or all of them as a file.
02

Study summary

The purpose of this study is to determine the recommended phase 2 dose (RP2D) of TAK-117 when administered in combination with docetaxel in participants with non-small cell lung cancer (NSCLC) and to evaluate efficacy, safety, and tolerability of TAK-117 administered alone and in combination with docetaxel at the RP2D in participants with locally advanced or metastatic non-small cell lung cancer.

Read the detailed description

The drug being evaluated in this study is called TAK-117. TAK-117 is tested in combination with docetaxel versus docetaxel alone for the treatment of non-small cell lung cancer (NSCLC).

This study consisted of 2 phases:

  • Phase 1b - dose escalation phase
  • Phase 2 - expansion phase.

The study enrolled 14 patients with NSCLC who have been treated with multiple prior lines of therapies will be enrolled for Phase 1b. The participants will receive docetaxel (36 mg/m\^2) intravenous (IV) and TAK-117 tablets, orally administered, once daily in 21-day dosing cycles. The TAK-117 dose will be escalated until recommended Phase 2 dose (RP2D) is determined.

Each part of the adaptive Phase 2 portion of the study is designed as a stand-alone, randomized study evaluating PFS as the primary efficacy measure in a total of 60 participants between the 2 treatment arms: TAK-117 plus docetaxel versus docetaxel alone. An event-driven analysis of PFS will be performed after each part of Phase 2. On the basis of the PFS analysis of the preceding part of the study, the study may be stopped for efficacy or futility, or proceed to the next part. However, Phase 2 of the study was cancelled.

Study drug will be administered in 21-day dosing cycles. During each phase of the study, participants will be treated with a maximum of 9 cycles of either docetaxel alone or docetaxel plus TAK-117. Subsequently, participants treated with docetaxel plus TAK-117 may continue to receive TAK-117 monotherapy until progression of disease, occurrence of unacceptable toxicities or death.

The maximum duration of treatment for participants will be 12 months unless it is determined that a participant would derive benefit from continued treatment beyond 12 months. Participants will continue to be followed after discontinuation of study drug to collect PFS and OS data. Participants may withdraw from therapy at any time.

This multicenter trial will be conducted in North America. The overall time to participate in this study is up to 24 months.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a and/or cytologically confirmed diagnosis of NSCLC (squamous or nonsquamous).

    • For Phase 2 of the study, has a diagnosis of mixed squamous and nonsquamous (or adenosquamous) NSLC.
  • Has locally advanced or disease (Stage IIIb or Stage IV) with radiographically or clinically evaluable lesions.
  • Has experienced failure of at least 1 prior chemotherapy regimen:

    • For Phase 2 of the study:
    • Participants must have received 1 prior platinum-based chemotherapy regimen (excluding a docetaxel-containing regimen) for advanced or metastatic (Stage IIIb or Stage IV) disease followed by documented progressive disease (PD).
    • A drug provided as maintenance therapy following cytotoxic chemotherapy will be considered to be part of that regimen.
    • Participants who received prior therapy with paclitaxel as a part of the platinum-based doublet front-line regimen without PD on therapy.
    • Participants who, after the front-line, platinum-based, non-docetaxel containing chemotherapy, have been treated with 1 line of nivolumab or other immune- but progressed on or after the therapy.
    • For Phase 1b of the study: Participants who have experienced failure of multiple are eligible.
    • For Phase 2, has archived or fresh tumor samples (obtained during screening) sufficient for genotyping.
  • Has adequate organ function, before the first dose of study drug.
  • Has (ECOG) Performance Status of 0 or 1.
  • Female participants who are for at least 1 year before the screening visit or are surgically sterile, or are of , agree to practice 1 highly effective method and 1 additional effective (barrier) method of , at the same time, from the time of signing the through 30 days (or longer, as mandated by local labeling) after the last dose of study drug, or agree to practice true abstinence.
  • Female participants must agree to not donate eggs (ova) during the course of this study and for 30 days after receiving their last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling.
  • Male participants agree to practice highly effective barrier contraception during the entire study treatment period and through 120 days after the last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling, or agree to practice true abstinence.
  • Male participants must agree to not donate sperm during the course of the study and for 120 days after receiving their last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling.
  • Has suitable venous access for the study-required blood sampling.
  • Has recovered (ie, \<= Grade 1 toxicity or eligibility per this protocol is met) from the reversible effects of prior anticancer therapy.
  • In the opinion of the investigator, the participant or legal guardian is capable of understanding and complying with protocol requirements for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Previous treatment with a PI3K or AKT inhibitor.
  • Prior cancer therapy or other therapy within 2 weeks before the first administration of study drug or failed to recover from the reversible effects of prior anticancer therapies. For prior therapies with a half-life longer than 3 days, the interval must be at least 28 days before the first administration of study drug, and the participant must have documented progressive disease.
  • Has poorly controlled diabetes mellitus defined as > 6.5%.
  • Has taken strong inhibitors or strong inducers of within 14 days before the first dose of study drug.
  • Has taken histamine-H2 receptor antagonists and/or neutralizing antacids within 24 hours before the first administration of study drug.
  • Has taken proton pump inhibitors within 7 days before the first administration of study drug.
  • Has a condition that requires the concomitant use of any of the protocol-excluded medications, supplements, or food products during the course of the study .
  • Has any co-morbidities.
  • Has acute myocardial infarction within 6 months before starting study drug, current or history of Class III or IV heart failure; evidence of current uncontrolled cardiovascular conditions including cardiac arrhythmias, angina, pulmonary hypertension, or (ECG) evidence of acute ischemia or active conduction system abnormalities; Fridericia's interval > 475 milliseconds (msec) (males) or > 450 msec (females) on a 12-lead ECG during the Screening period; or abnormalities on 12-lead ECG including, but not limited to, changes in rhythm and intervals that in the opinion of the investigator are considered to be clinically significant.
  • Has known, previously diagnosed infection or active chronic or C.
  • Has , unless has completed definitive therapy, is not on , has a stable neurologic status for at least 2 weeks after completion of the definitive therapy and steroids, and does not have neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.
  • Has active secondary that requires treatment.
  • Has any serious medical or psychiatric illness, including drug or alcohol abuse.
  • Male participants who intend to donate sperm during the course of this study or 120 days after receiving their last dose of TAK-117 and, for docetaxel, for as long as is mandated by local labeling.
  • Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period or a positive urine pregnancy test on Day 1 before administration of the first dose of study drug.
  • Is unwilling or unable to abide by the requirements of the study.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    TAK-117 200 mg + Docetaxel (36 mg/m^2)

    TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m\^2, intravenous (IV) infusion, on Days 1 and 8 of the 21-day cycle up ro Cycle 9 (approximately 189 days).

    Drug: Docetaxel · Drug: TAK-117

  • Experimental
    TAK-117 300 mg + Docetaxel 36 mg/m^2

    TAK-117 200 mg, tablets, orally on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of the 21-day cycle and docetaxel 36 mg/m\^2, IV infusion, on Days 1 and 8 of the 21-day cycle up to 6 cycles (approximately 126 days).

    Drug: Docetaxel · Drug: TAK-117

  • Experimental
    Phase 2 - TAK-117 + Docetaxel 36 mg/m^2

    TAK-117 tablets, at the dose determined in the dose escalation phase, on Days 2, 3, 4, 9, 10, 11, 16, 17, and 18 of a 21-day cycle plus Docetaxel 36 mg/m\^2 IV infusion on Days 1 and 8 of a 21-day cycle.

    Drug: Docetaxel · Drug: TAK-117

  • Experimental
    Phase 2 - Docetaxel 75 mg/m^2

    Docetaxel 75 mg/m\^2, IV infusion once every 3 weeks (per approved prescribing information) with dosing on Day 1 of each 21-day cycle.

    Drug: Docetaxel · Drug: TAK-117

Interventions

  • Docetaxel intravenous infusion

  • TAK-117 Tablets

    Also known as: MLN1117

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicity (DLT) in Phase 1b

    DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia or thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. ≥Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 4 hematologic toxicity; 6. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 arthralgia/myalgia, ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 Rash, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 1 with appropriate treatment; 7. Inability to administer at least 75% of planned doses; 8. Clinically significant occurrence per investigator that is a safety risk.

    Time frame: Cycle 1 (Up to Day 21)

  2. Maximum Tolerated Dose (MTD) of TAK-117 in Combination With Docetaxel 36 mg/m^2 in Phase 1b

    The MTD is defined as the dose of TAK-117 in combination with docetaxel 36 mg/m\^2 at which 1 of 6 evaluable participants experience DLT. DLT was evaluated according to NCI CTCAE version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia or thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. ≥Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 4 hematologic toxicity; 6. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 arthralgia/myalgia, ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 Rash, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 1 with appropriate treatment; 7. Inability to administer at least 75% of planned doses; 8. Clinically significant occurrence per investigator that is a safety risk.

    Time frame: Cycle 1 (Up to Day 21)

  3. Recommended Phase 2 Dose of TAK-117 in Phase 1b

    The recommended phase 2 dose was determined in Phase 1b based on participant dose-limiting toxicities and the maximum tolerated dose.

    Time frame: Cycle 1 (Up to Day 21)

  4. Progression-Free Survival (PFS) in Phase 2

    PFS is defined as the time from the date randomization to the date of first documented progressive disease (PD) or death as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.

    Time frame: Approximately 12 months in Phase 2

Secondary outcomes

  1. Number of Participants With Significant Change in Vital Signs Reported as Adverse Events in Phase 1b

    Clinically significant change from baseline in vital sign measures will be assessed. Vital sign measurements included measurements of diastolic and systolic blood pressure, heart rate, and temperature.

    Time frame: First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)

  2. Number of Participants With Significant Change in Physical Examination Reported as Adverse Events in Phase 1b

    Physical examination consists of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and (11) physical examinations other than body systems described in (1) to (10).

    Time frame: First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)

  3. Number of Participants With Electrocardiogram (ECG) Findings Reported as Adverse Events in Phase 1b

    A standard 12-lead ECG was performed.

    Time frame: First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)

  4. Number of Participants With Clinically Significant Change in Clinical Laboratory Tests Reported as Adverse Events in Phase 1b

    The number of participants with any markedly abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout study.

    Time frame: First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Phase 1b

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: From first dose of study drug to 30 days after last dose of study drug (Up to Day 223)

  6. Number of Participants With Significant Change in Vital Signs Reported as Adverse Events in Phase 2

    Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.

    Time frame: Approximately 12 months in Phase 2

  7. Number of Participants With Significant Change in Physical Examination Reported as Adverse Events in Phase 2

    Physical examination consists of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and (11) physical examinations other than body systems described in (1) to (10).

    Time frame: Approximately 12 months in Phase 2

  8. Number of Participants With Electrocardiogram (ECG) Findings Reported as Adverse Events in Phase 2

    Clinically significant changes from baseline in ECGs will be tabulated by time point including any unscheduled measurements.

    Time frame: Approximately 12 months in Phase 2

  9. Number of Participants With Clinically Significant Change in Clinical Laboratory Tests Reported as Adverse Events in Phase 2

    The number of participants with any markedly abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout study.

    Time frame: Approximately 12 months in Phase 2

  10. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Phase 2

    An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

    Time frame: Approximately 12 months in Phase 2

  11. Response Rate in Phase 2

    Response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.

    Time frame: Approximately 12 months in Phase 2

  12. Disease Control Rate in Phase 2

    Disease control rate is defined as percentage of participants with CR + PR + stable disease (SD). According to RECIST: CR is defined as disappearance of all target lesions, PR is defined as 30% decrease in the sum of the longest diameter of target lesions and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter (LD) since the treatment started.

    Time frame: Approximately 12 months in Phase 2

  13. Duration of Response in Phase 2

    The duration of response is defined as the time from the date of first documentation of a response to the date of first documentation of progression of disease. As per RECIST 1.1, PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.

    Time frame: Approximately 12 months in Phase 2

  14. Time to Progression in Phase 2

    Time to progression is defined as the time from the date of randomization to the date of first documentation of progression of disease. As per RECIST 1.1, PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.

    Time frame: Approximately 12 months in Phase 2

  15. Overall Survival (OS) in Phase 2

    Overall survival is defined as the time from the date of randomization to the date of death.

    Time frame: Approximately 12 months in Phase 2

  16. TAK-117 Plasma Concentration in Phase 1b

    Time frame: Cycle 1 Day 1 pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose

  17. Cmax: Maximum Observed Plasma Concentration for TAK-117

    Time frame: Cycle 1 Day 1 pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose

  18. Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117

    Time frame: Cycle 1 Day 1 pre-dose and up to 24 hours post-dose

  19. AUCtau: Area Under the Concentration Time Curve From Time 0 to the Next Dose in Phase 1b for TAK-117

    Time frame: Cycle 1 Day 1 pre-dose and up to 24 hours post-dose

  20. AUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Phase 1b for TAK-117

    Time frame: Cycle 1 Day 1 pre-dose and up to 24 hours post-dose

  21. CL/F: Oral Clearance for TAK-117

    Time frame: Cycle 1 Day 1 pre-dose and up to 24 hours post-dose

  22. T1/2: Terminal Phase Elimination Half-life (T1/2) for TAK-117

    Time frame: Cycle 1 Day 1 pre-dose and up to 24 hours post-dose

  23. TAK-117 Plasma Concentrations When Administered 1 Day After Docetaxel in Phase 2

    Time frame: 1 day post docetaxel dose

07

Results

Posted Feb 7, 2018

Participant flow

Participants took part in the study at 5 investigative sites in United States and 1 in Canada from 03 June 2015 to 20 January 2017. The Phase 2 portion of the study was cancelled by the sponsor.

Participant flow — Overall Study
MilestonePhase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2Phase 2 - TAK-117 + Docetaxel 36 mg/m^2Phase 2 - Docetaxel 75 mg/m^2
Started6800
Completed0000
Not completed6800
Withdrew: Study terminated by sponsor1100
Withdrew: Withdrawal by patient1000
Withdrew: Death2200
Withdrew: Death due to disease progression2200
Withdrew: Death from legionella infection0100
Withdrew: Patient seen by another oncologist0100
Withdrew: Lost to follow-up0100

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicity (DLT) in Phase 1b

DLT was evaluated according to National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia or thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. ≥Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 4 hematologic toxicity; 6. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 arthralgia/myalgia, ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 Rash, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 1 with appropriate treatment; 7. Inability to administer at least 75% of planned doses; 8. Clinically significant occurrence per investigator that is a safety risk.

Time frame:
Cycle 1 (Up to Day 21)
Reported as:
Number · participants
Number of Participants With Dose-Limiting Toxicity (DLT) in Phase 1b
participantsPhase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2
Number of Participants With Dose-Limiting Toxicity (DLT) in Phase 1b01
PrimaryMaximum Tolerated Dose (MTD) of TAK-117 in Combination With Docetaxel 36 mg/m^2 in Phase 1b

The MTD is defined as the dose of TAK-117 in combination with docetaxel 36 mg/m\^2 at which 1 of 6 evaluable participants experience DLT. DLT was evaluated according to NCI CTCAE version 4.03 and was defined as any of the following events: 1. Grade 4 neutropenia or thrombocytopenia lasting ≥7 consecutive days; 2. Grade 4 neutropenia with fever and/or infection; 3. Platelet count \<10,000/mm\^3; 4. ≥Grade 3 thrombocytopenia with bleeding; 5. Any other ≥Grade 4 hematologic toxicity; 6. Any other ≥Grade 3 nonhematologic toxicity, with following exceptions: ≥Grade 3 arthralgia/myalgia, ≥Grade 3 nausea/emesis, ≥Grade 3 diarrhoea, Grade 3 fatigue, Grade 3 Rash, Grade 3 nonhematological toxicity that could be controlled to ≤Grade 1 with appropriate treatment; 7. Inability to administer at least 75% of planned doses; 8. Clinically significant occurrence per investigator that is a safety risk.

Time frame:
Cycle 1 (Up to Day 21)
Reported as:
Number · mg
Maximum Tolerated Dose (MTD) of TAK-117 in Combination With Docetaxel 36 mg/m^2 in Phase 1b
mgTAK-117 + Docetaxel
Maximum Tolerated Dose (MTD) of TAK-117 in Combination With Docetaxel 36 mg/m^2 in Phase 1b300
PrimaryRecommended Phase 2 Dose of TAK-117 in Phase 1b

The recommended phase 2 dose was determined in Phase 1b based on participant dose-limiting toxicities and the maximum tolerated dose.

Time frame:
Cycle 1 (Up to Day 21)
Reported as:
Number · mg
Recommended Phase 2 Dose of TAK-117 in Phase 1b
mgTAK-117 + Docetaxel
Recommended Phase 2 Dose of TAK-117 in Phase 1b200
PrimaryProgression-Free Survival (PFS) in Phase 2

PFS is defined as the time from the date randomization to the date of first documented progressive disease (PD) or death as assessed by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria. PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryNumber of Participants With Significant Change in Vital Signs Reported as Adverse Events in Phase 1b

Clinically significant change from baseline in vital sign measures will be assessed. Vital sign measurements included measurements of diastolic and systolic blood pressure, heart rate, and temperature.

Time frame:
First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)
Reported as:
Number · participants
Number of Participants With Significant Change in Vital Signs Reported as Adverse Events in Phase 1b
participantsPhase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2
Bradycardia10
Sinus tachycardia01
SecondaryNumber of Participants With Significant Change in Physical Examination Reported as Adverse Events in Phase 1b

Physical examination consists of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and (11) physical examinations other than body systems described in (1) to (10).

Time frame:
First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)
Reported as:
Number · participants
Number of Participants With Significant Change in Physical Examination Reported as Adverse Events in Phase 1b
participantsPhase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2
Number of Participants With Significant Change in Physical Examination Reported as Adverse Events in Phase 1b01
SecondaryNumber of Participants With Electrocardiogram (ECG) Findings Reported as Adverse Events in Phase 1b

A standard 12-lead ECG was performed.

Time frame:
First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)
Reported as:
Number · participants
Number of Participants With Electrocardiogram (ECG) Findings Reported as Adverse Events in Phase 1b
participantsPhase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2
Bradycardia10
Tachycardia01
SecondaryNumber of Participants With Clinically Significant Change in Clinical Laboratory Tests Reported as Adverse Events in Phase 1b

The number of participants with any markedly abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout study.

Time frame:
First dose of study drug through 30 days after the last dose of study drug (Up to Day 223)
Reported as:
Number · participants
Number of Participants With Clinically Significant Change in Clinical Laboratory Tests Reported as Adverse Events in Phase 1b
participantsPhase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2
Anemia22
Hypokalemia13
Hypomagnesemia03
Hypophosphatemia03
Aspartate aminotransferase increased12
Febrile neutropenia12
Hyponatremia12
Hyperglycemia02
Leukopenia01
Pancytopenia01
Thrombocytopenia10
Blood creatinine increased11
Alanine aminotransferase increased01
Blood cholesterol increased01
Neutrophil count decreased10
White blood cell count decreased01
Hyperkalaemia10
Hypernatraemia01
Hypoalbuminaemia10
Hypocalcaemia01
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Phase 1b

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
From first dose of study drug to 30 days after last dose of study drug (Up to Day 223)
Reported as:
Number · participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Phase 1b
participantsPhase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2
TEAEs68
SAEs56
SecondaryNumber of Participants With Significant Change in Vital Signs Reported as Adverse Events in Phase 2

Vital signs (blood pressure, pulse rate, and oral temperature) measurements were collected throughout the study.

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryNumber of Participants With Significant Change in Physical Examination Reported as Adverse Events in Phase 2

Physical examination consists of examinations of the following body systems: (1) eyes; (2) ears, nose, throat; (3) cardiovascular system; (4) respiratory system; (5) gastrointestinal system; (6) dermatologic system; (7) extremities; (8) musculoskeletal system; (9) nervous system; (10) lymph nodes; and (11) physical examinations other than body systems described in (1) to (10).

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryNumber of Participants With Electrocardiogram (ECG) Findings Reported as Adverse Events in Phase 2

Clinically significant changes from baseline in ECGs will be tabulated by time point including any unscheduled measurements.

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryNumber of Participants With Clinically Significant Change in Clinical Laboratory Tests Reported as Adverse Events in Phase 2

The number of participants with any markedly abnormal standard safety laboratory values (Chemistry, Hematology and Urinalysis) collected throughout study.

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) in Phase 2

An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. A serious adverse event (SAE) is any untoward medical occurrence or effect that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability / incapacity, is a congenital anomaly / birth defect or is medically important due to other reasons than the above mentioned criteria. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug.

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryResponse Rate in Phase 2

Response rate is defined as the percentage of participants with Complete Response (CR) + Partial Response (PR) as assessed by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1. According to RECIST: CR is defined as disappearance of all target lesions and PR is defined as 30% decrease in the sum of the longest diameter of target lesions.

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryDisease Control Rate in Phase 2

Disease control rate is defined as percentage of participants with CR + PR + stable disease (SD). According to RECIST: CR is defined as disappearance of all target lesions, PR is defined as 30% decrease in the sum of the longest diameter of target lesions and SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum longest diameter (LD) since the treatment started.

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryDuration of Response in Phase 2

The duration of response is defined as the time from the date of first documentation of a response to the date of first documentation of progression of disease. As per RECIST 1.1, PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryTime to Progression in Phase 2

Time to progression is defined as the time from the date of randomization to the date of first documentation of progression of disease. As per RECIST 1.1, PD is defined as 20% increase in the sum of the longest diameter of target lesions for measurable neoplastic disease.

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryOverall Survival (OS) in Phase 2

Overall survival is defined as the time from the date of randomization to the date of death.

Time frame:
Approximately 12 months in Phase 2

No measurements were reported for this outcome.

SecondaryTAK-117 Plasma Concentration in Phase 1b
Time frame:
Cycle 1 Day 1 pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose
Reported as:
Mean · ng/mL
TAK-117 Plasma Concentration in Phase 1b
ng/mLPhase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2
Predose114.00 ± 254.9120.00 ± 0.000
0.5 Hour Postdose1208.60 ± 1080.782847.39 ± 966.346
1 Hour Postdose1907.00 ± 1307.1241973.29 ± 1688.210
2 Hours Postdose2597.83 ± 1612.2333021.43 ± 2162.417
4 Hours Postdose2477.50 ± 1407.4654185.71 ± 2156.439
6 Hours Postdose2143.00 ± 1290.3953648.57 ± 1636.892
8 Hours Postdose1902.50 ± 1210.5533677.14 ± 1941.020
24 Hours Postdose652.17 ± 472.3151771.57 ± 1347.864
SecondaryCmax: Maximum Observed Plasma Concentration for TAK-117
Time frame:
Cycle 1 Day 1 pre-dose and 0.5, 1, 2, 4, 6, 8 and 24 hours post-dose

No measurements were reported for this outcome.

SecondaryTmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-117
Time frame:
Cycle 1 Day 1 pre-dose and up to 24 hours post-dose

No measurements were reported for this outcome.

SecondaryAUCtau: Area Under the Concentration Time Curve From Time 0 to the Next Dose in Phase 1b for TAK-117
Time frame:
Cycle 1 Day 1 pre-dose and up to 24 hours post-dose

No measurements were reported for this outcome.

SecondaryAUC(Last): Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration in Phase 1b for TAK-117
Time frame:
Cycle 1 Day 1 pre-dose and up to 24 hours post-dose

No measurements were reported for this outcome.

SecondaryCL/F: Oral Clearance for TAK-117
Time frame:
Cycle 1 Day 1 pre-dose and up to 24 hours post-dose

No measurements were reported for this outcome.

SecondaryT1/2: Terminal Phase Elimination Half-life (T1/2) for TAK-117
Time frame:
Cycle 1 Day 1 pre-dose and up to 24 hours post-dose

No measurements were reported for this outcome.

SecondaryTAK-117 Plasma Concentrations When Administered 1 Day After Docetaxel in Phase 2
Time frame:
1 day post docetaxel dose

No measurements were reported for this outcome.

Adverse events

Collected over First dose of study drug through 30 days from the last dose (up to Day 223). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^21/6 (16.7%)5/6 (83.3%)6/6 (100%)
Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^23/8 (37.5%)6/8 (75%)8/8 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPhase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2
PneumoniaInfections and infestations2/61/8
DiarrhoeaGastrointestinal disorders2/61/8
Respiratory failureRespiratory, thoracic and mediastinal disorders2/60/8
NauseaGastrointestinal disorders0/62/8
VomitingGastrointestinal disorders0/62/8
Febrile neutropeniaBlood and lymphatic system disorders1/62/8
DehydrationMetabolism and nutrition disorders0/62/8
Gastric haemorrhageGastrointestinal disorders1/60/8
StomatitisGastrointestinal disorders1/60/8
Cardio-respiratory arrestCardiac disorders1/60/8
Most frequent other events
Showing 10 of 70
Most frequent other events
EventPhase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2
NauseaGastrointestinal disorders2/65/8
DiarrhoeaGastrointestinal disorders1/65/8
FatigueGeneral disorders3/64/8
DyspnoeaRespiratory, thoracic and mediastinal disorders2/63/8
Decreased appetiteMetabolism and nutrition disorders1/63/8
HypokalaemiaMetabolism and nutrition disorders1/63/8
HypomagnesaemiaMetabolism and nutrition disorders0/63/8
HypophosphataemiaMetabolism and nutrition disorders0/63/8
AnaemiaBlood and lymphatic system disorders2/62/8
Oedema peripheralGeneral disorders2/62/8

Baseline characteristics

Baseline characteristics were assessed for enrolled participants.

Age, Continuous
Age, Continuous(years)Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2Total
Mean64.0 ± 8.1062.1 ± 11.3262.9 ± 9.75
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2Total
Female123
Male5611
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2Total
Hispanic or Latino101
Not Hispanic or Latino5712
Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2Total
White459
Black or African American123
Asian101
Not reported011
Height
Height(cm)Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2Total
Mean171.53 ± 5.854172.95 ± 6.102172.34 ± 5.810
Weight
Weight(kg)Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2Total
Mean69.48 ± 21.63072.69 ± 9.15771.31 ± 15.093
Body Surface Area
Body Surface Area(m^2)Phase 1 - TAK-117 200 mg + Docetaxel 36 mg/m^2Phase 1 - TAK-117 300 mg + Docetaxel 36 mg/m^2Total
Mean1.805 ± 0.29871.865 ± 0.12311.839 ± 0.2084
08

Study locations

11 sites
  • San Diego, California, United States
  • Atlanta, Georgia, United States
  • Farmington Hills, Michigan, United States
  • Rochester, Minnesota, United States
  • Saint Louis, Missouri, United States
  • Chattanooga, Tennessee, United States
  • Edmonton, Alberta, Canada
  • Toronto, Ontario, Canada
  • Amsterdam, Netherlands
  • Hoofddorp, Netherlands
  • Maastricht, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Jan 2017, 19 months.

Results were first posted in Feb 2018, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2015
First posted
Mar 19, 2015
StartActual
Jun 3, 2015
Primary completionActual
Jan 12, 2017
CompletionActual
Jan 20, 2017
Results first posted
Feb 7, 2018
Last update
Feb 7, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02393209
Responsible party
Sponsor
First posted
Mar 19, 2015
Start date
Jun 3, 2015
Primary completion
Jan 12, 2017
Completion
Jan 20, 2017
Results posted
Feb 7, 2018
Last update
Feb 7, 2018

Study contacts

Medical Director Clinical Science
study director · Millennium Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Serabelisib

Start the discussion